Chemotherapy plus immunotherapy with different radiation doses for early-stage breast cancer
Part of Cancer clinical trials.
This trial tests a combination of chemotherapy, an immunotherapy drug, and two different schedules of radiation before surgery for a common type of breast cancer. The goal is to find which radiation approach works better and to improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of breast cancer called HR-positive/HER2-negative, confirmed by biopsy.
- Your tumor is at a certain size and may have spread to nearby lymph nodes, but not to distant parts of the body.
- You are generally healthy and able to perform daily activities (ECOG score 0-1).
- Your blood counts (red cells, white cells, platelets) and liver, kidney, and heart function are within normal limits.
- You have not had chemotherapy or radiation before, and you do not have other serious medical conditions that would make this treatment unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy, immunotherapy, and targeted radiation given before surgery for a certain type of breast cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests adding anlotinib (a targeted therapy) and benmelstobart (an immunotherapy) to standard chemotherapy before surgery for a specific type of breast cancer. It may help shrink tumors and improve outcomes for patients whose tumors have certain markers.
This trial tests adding the immunotherapy drug serplulimab to standard chemotherapy for people with early-stage HR-positive, HER2-negative breast cancer. It aims to see if this combination can improve outcomes before surgery.
This trial tests a new drug combination given before surgery for early-stage, hormone receptor-positive breast cancer. It aims to see if this approach can improve outcomes for patients with high-risk features.
This trial tests whether combining targeted radiation (SBRT) with immunotherapy (PD-1 inhibitor) and chemotherapy can improve outcomes for people with early-stage triple-negative breast cancer that has not spread far. It aims to find a more effective treatment option.
This trial is testing a new treatment approach for patients with a certain type of breast cancer (HR+/HER2-). It combines radiation therapy with chemotherapy and an immunotherapy drug before the patient's main surgery, to see if it can shrink or eliminate the tumor more effectively.
Hear when a new HR+/HER2- Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.